664 related articles for article (PubMed ID: 22260846)
1. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M; Bell R; Dang C
Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
[TBL] [Abstract][Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. Epirubicin as adjuvant therapy in breast cancer.
Earl H; Iddawela M
Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
Ormrod D; Holm K; Goa K; Spencer C
Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
[TBL] [Abstract][Full Text] [Related]
5. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
Findlay BP; Walker-Dilks C
Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
10. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin in combination with the taxanes.
Trudeau M; Pagani O
Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
[TBL] [Abstract][Full Text] [Related]
13. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Lück HJ; Thomssen C; Du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):36-9. PubMed ID: 9516602
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin.
Glück S
Oncologist; 2005; 10(10):780-91. PubMed ID: 16314288
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy during pregnancy: what is really safe?
Peccatori F; Martinelli G; Gentilini O; Goldhirsch A
Lancet Oncol; 2004 Jul; 5(7):398. PubMed ID: 15231245
[No Abstract] [Full Text] [Related]
18. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Abbate A; De Marco E; Mezzaroma E; Di Persio S; Frati G; Loperfido F; Biondi-Zoccai G
Int J Cardiol; 2013 Aug; 167(3):1055-7. PubMed ID: 23174173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
